Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
(WorldNews Belgium)

Regulated information 22 March 2017, 7.30 CET Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 Triggers a $7.5 M milestone payment from AbbVie Third potentiator in growing portfolio of cystic fibrosis drug candidates Mechelen, Belgium; 22 March 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with novel potentiator GLPG3067 for cystic fibrosis (CF) in a Phase 1 study. Galapagos is to receive a $7.5 million milestone payment from its collaboration partner AbbVie for this achievement. The aim of the Phase 1 study is to evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG0367. The...